Translate
Viridian Therapeutics, Inc.
About
Viridian Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 7 2026
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
May 5 2026
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
Mar 30 2026
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
Mar 19 2026
Bambusa Therapeutics Appoints Todd James Chief Financial Officer
Feb 26 2026
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results